Taysha Gene Therapies CEO Sean Nolan's 2023 pay slips 20% to $1.5M
Taysha Gene Therapies reports 2023 executive compensation
By ExecPay News
Published: April 18, 2024
Taysha Gene Therapies reported fiscal year 2023 executive compensation information on April 18, 2024.
In 2023, three executives at Taysha Gene Therapies received on average a compensation package of $1.2M, a 22% decrease compared to previous year.
Average pay of disclosed executives at Taysha Gene Therapies
Sean Nolan, Chief Executive Officer, received $1.5M in total, which decreased by 20% compared to 2022. 39% of Nolan's compensation, or $600K, was in salary. Nolan also received $324K in non-equity incentive plan, $597K in option awards, as well as $1.3K in other compensation.
Sukumar Nagendran, President and Head of Research and Development, received a compensation package of $1.2M, which decreased by 8% compared to previous year. 45% of the compensation package, or $565K, was in salary.
Kamran Alam, Chief Financial Officer, earned $975K in 2023, a 19% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 18, 2024.